Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB

Thorax
Anne AsplerDick Menzies

Abstract

Treatment for latent tuberculosis infection with isoniazid for 9 months (9INH) has poor completion and serious adverse events, while treatment for 4 months with daily rifampin (4RIF) has significantly higher completion and fewer adverse events. To compare the health system costs of 4RIF and 9INH. In a randomised trial conducted in five Canadian centres, one Brazilian and one Saudi Arabian centre, consenting subjects were randomised to receive 4RIF or 9INH. Health system costs were estimated from healthcare utilisation including scheduled and unscheduled visits, investigations and drugs. All activities for all subjects were evaluated using financial information from 2007 from the Montreal Chest Institute. Costs were expressed in Canadian dollars. Total health system cost per patient allocated to 4RIF was $854 compared with $970 for 9INH (p<0.0001). The average cost per patient for the 328 of 420 (78%) who completed 4RIF therapy was $1094 compared with $1625 for the 254 of 427 (60%) completing 9INH (p<0.0001). Costs were modestly increased in patients with minor intolerance and substantially increased if the treating physician stopped treatment because of possible adverse events. Total costs related to management of adverse event...Continue Reading

Citations

Jun 3, 2004·American Journal of Respiratory and Critical Care Medicine·Dick MenziesKevin Schwartzman
May 9, 2012·American Journal of Respiratory and Critical Care Medicine·Kevin P CainConnie A Haley
Dec 12, 2012·Infection and Drug Resistance·Brianna L Norton, David P Holland
May 26, 2011·Expert Review of Anti-infective Therapy·Benjamin M Smith, Dick Menzies
Oct 22, 2011·Expert Opinion on Investigational Drugs·Sadhna Sharma, Amandeep Singh
May 1, 2012·Revue des maladies respiratoires·P Fraisse, UNKNOWN Groupe tuberculose de la SPLF
Mar 8, 2013·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·A K SubramanianUNKNOWN AST Infectious Diseases Community of Practice
Nov 19, 2014·Evidence-based Child Health : a Cochrane Review Journal·Surendra K SharmaPrathap Tharyan
May 13, 2015·Journal of Comparative Effectiveness Research·Kyle R Fluegge, Brian E Roe
Apr 9, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Y MeijeUNKNOWN ESCMID Study Group of Infection in Compromised Hosts
May 18, 2016·BMC Infectious Diseases·Andreas SandgrenMarieke J van der Werf
Dec 31, 2011·The Journal of Infection·Jann-Yuan WangPan-Chyr Yang
Sep 24, 2013·Therapeutic Advances in Respiratory Disease·Madhavi J Parekh, Neil W Schluger
Nov 8, 2018·Annual Review of Medicine·Jeffrey A Tornheim, Kelly E Dooley
Mar 1, 2019·Clinical Transplantation·Aruna K SubramanianUNKNOWN Infectious Diseases Community of Practice of the American Society of Transplantation
Jul 13, 2019·Canadian Journal of Public Health = Revue Canadienne De Santé Publique·Pierre J PlourdeLisa M Lix
Nov 28, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andrew G FlynnRobert Belknap
Jan 31, 2018·Transplantation·Guilherme Santoro-LopesOscar Len
Nov 21, 2018·BMC Infectious Diseases·Yvette Louise ScheinBrita Askeland Winje
Aug 2, 2018·The New England Journal of Medicine·Dick MenziesAndrea Benedetti
Nov 22, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kunchok DorjeeRichard E Chaisson
Apr 15, 2017·Microbiology Spectrum·Connie A Haley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Related Papers

American Journal of Respiratory and Critical Care Medicine
David P HollandJason E Stout
Respirology : Official Journal of the Asian Pacific Society of Respirology
Philip Lobue, Dick Menzies
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Javier Ena, Victoria Valls
© 2021 Meta ULC. All rights reserved